Epitalon vs MOTS-c
Both are sold as longevity injectables with no approval, but they fail different tests: MOTS-c has credible science and no human trials, epitalon has human claims nobody has replicated.
Short answer
Epitalon rests on firmer ground than MOTS-c, with human clinical data against only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on telomerase activation and life extension has trial data to go on with Epitalon; MOTS-c, marketed for metabolism, endurance and longevity, is still an early-research option.
Epitalon
Epithalon
Marketed for telomerase activation and life extension, but the supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
Full Epitalon evidence reviewMOTS-c
A genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise — but no human outcome trials.
Full MOTS-c evidence reviewEpitalon vs MOTS-c: head to head
- FDA status / approved use
Epitalon
Not an approved drug in the US; sold as research-use-only materialMOTS-c
Not FDA-approved for any use; sold as a research-use-only injectable- Marketed for
Epitalon
Telomerase activation, life extensionMOTS-c
Metabolism, endurance, longevity- Outcome areas
Epitalon
Longevity / lifespan; Cellular senescenceMOTS-c
Mitochondrial / cellular energy; Exercise performance / endurance; Longevity / lifespan- Evidence grade
Epitalon
Clinical dataMOTS-c
Preclinical / minimal- How it works
Epitalon
Claimed to activate telomerase and normalize melatonin rhythm; claims are unreplicatedMOTS-c
Mitochondrial peptide targeting the folate-AICAR-AMPK energy-sensing pathway- Route and dosing
Epitalon
Injectable peptide sold in research vialsMOTS-c
Injection- Headline human result
Epitalon
Not establishedMOTS-c
Not established- Strongest evidence
Epitalon
Korkushko, Bull Exp Biol Med 2011Epitalon evidence reviewPubMed 22451889MOTS-c
Lee, Cell Metab 2015. Little or no controlled human outcome data for the marketed useMOTS-c evidence reviewPubMed 25738459- Key safety signal
Epitalon
Near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterilityMOTS-c
No long-term human safety data; research vials of unverified identity, dose, purity and sterility- How it is obtained
Epitalon
Sold gray-market as a research chemical; no approved or legitimately compounded human productMOTS-c
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| Epitalon | MOTS-c | |
|---|---|---|
| FDA status / approved use | Not an approved drug in the US; sold as research-use-only material | Not FDA-approved for any use; sold as a research-use-only injectable |
| Marketed for | Telomerase activation, life extension | Metabolism, endurance, longevity |
| Outcome areas | Longevity / lifespan; Cellular senescence | Mitochondrial / cellular energy; Exercise performance / endurance; Longevity / lifespan |
| Evidence grade | Clinical data | Preclinical / minimal |
| How it works | Claimed to activate telomerase and normalize melatonin rhythm; claims are unreplicated | Mitochondrial peptide targeting the folate-AICAR-AMPK energy-sensing pathway |
| Route and dosing | Injectable peptide sold in research vials | Injection |
| Headline human result | Not established | Not established |
| Strongest evidence | Korkushko, Bull Exp Biol Med 2011Epitalon evidence reviewPubMed 22451889 | Lee, Cell Metab 2015. Little or no controlled human outcome data for the marketed useMOTS-c evidence reviewPubMed 25738459 |
| Key safety signal | Near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterility | No long-term human safety data; research vials of unverified identity, dose, purity and sterility |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
MOTS-c is preclinical, yet its biology is modern, mechanistically characterized, and taken seriously by mitochondrial researchers; the gap is simply that no randomized human trial exists. Epitalon's problem is different and harder to excuse: the telomerase, melatonin-rhythm, and human mortality claims trace almost entirely to a single St. Petersburg group, cluster around 2001 to 2011, and have not been independently replicated. Neither is FDA-approved and both circulate as research-use-only material of unverified identity, purity, and dose, so neither is a consumer product. Judged on evidence quality rather than claim size, MOTS-c is the more defensible science and epitalon the more oversold pitch.
Epitalon fits if
Epitalon is worth reading mainly as a case study in how a confident anti-aging narrative gets built on old, small, single-source studies.
MOTS-c fits if
MOTS-c is the better fit for a reader who wants genuine mitochondrial biology and can live with the fact that every human claim is still extrapolation from animals.
Epitalon vs MOTS-c: common questions
- Is either Epitalon or MOTS-c FDA-approved?
- No. Epitalon is not an approved drug in the US; sold as research-use-only material. MOTS-c is not FDA-approved for any use; sold as a research-use-only injectable.
- Which has stronger human evidence, Epitalon or MOTS-c?
- Epitalon. It has human clinical data (key source: Korkushko, Bull Exp Biol Med 2011), while MOTS-c has only preclinical or minimal evidence (key source: Lee, Cell Metab 2015).
- What are the main safety concerns with Epitalon and MOTS-c?
- Epitalon has near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterility. MOTS-c has no long-term human safety data; research vials of unverified identity, dose, purity and sterility.
Key studies behind each
Epitalon
- Khavinson VKh, Shataeva LK, Chernova AA. (2003). Effect of regulatory peptides on gene transcription. Bull Exp Biol Med. PubMed 14666197
- Korkushko OV, Lapin BA, Goncharova ND, et al. (2007). Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. PubMed 17969590
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. PubMed 12937682
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. PubMed 15455129
MOTS-c
- Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed 25738459
- Kim SJ, Miller B, Mehta HH, et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. PubMed 31293078
- Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. PubMed 33473109
- Kim SJ, Miller B, Kumagai H, et al. (2021). Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. PubMed 32910336
The full evidence reviews
- Epitalon (epithalon): the honest evidence behind the telomerase and longevity claims
Marketed for telomerase activation and life extension. The supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
Updated August 2026
- MOTS-c peptide: benefits, side effects and what the evidence shows
Real mitochondrial biology, absent human evidence: a genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise, but no human outcome trials. Promising biology, not a proven therapeutic.
Updated October 2026